-
Product Insights
NewLikelihood of Approval Analysis for Acne And Related Disorders
Overview How likely is it that the drugs in Acne And Related Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acne And Related Disorders Overview Acne and related disorders encompass...
-
Product Insights
NewLikelihood of Approval Analysis for Age Related Macular Degeneration
Overview How likely is it that the drugs in Age Related Macular Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Age Related Macular Degeneration Overview Macular degeneration, also known as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLK-401 in Age Related Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLK-401 in Age Related Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLK-401 in Age Related Macular Degeneration Drug Details: GLK-401 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) Drug Details: Obexelimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abatacept in Immunoglobulin G4-Related Disease (IgG4-RD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abatacept in Immunoglobulin G4-Related Disease (IgG4-RD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abatacept in Immunoglobulin G4-Related Disease (IgG4-RD) Drug Details: Abatacept...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dupilumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Immunoglobulin G4-Related Disease (IgG4-RD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dupilumab in Immunoglobulin G4-Related Disease (IgG4-RD) Drug Details: Dupilumab (REGN-668,...
-
Product Insights
Angiopoietin Related Protein 3 – Drugs In Development, 2023
Global Markets Direct’s Angiopoietin Related Protein 3 provides in depth analysis on Angiopoietin Related Protein 3 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Angiopoietin Related Protein...
-
Product Insights
Low Density Lipoprotein Receptor Related Protein – Drugs In Development, 2023
Global Markets Direct’s Low Density Lipoprotein Receptor Related Protein provides in depth analysis on Low Density Lipoprotein Receptor Related Protein targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Nuclear Factor Erythroid 2 Related Factor 2 – Drugs In Development, 2023
Global Markets Direct’s Nuclear Factor Erythroid 2 Related Factor 2 provides in depth analysis on Nuclear Factor Erythroid 2 Related Factor 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...